Citadel Advisors
BLPH

Citadel Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Citadel Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,717
Closed -$17.1K – 15759
2023
Q3 		$17.1K Buy
+42,717
New +$21K ﹤0.01% 12744
2021
Q2 		– Sell
-20,000
Closed -$104K – 15012
2021
Q1 		$104K Buy
+20,000
New +$139K ﹤0.01% 12445
2019
Q4 		– Sell
-5,516
Closed -$40K – 10126
2019
Q3 		$40K Buy
5,516
+1,373
+33% +$12.5K ﹤0.01% 8775
2019
Q2 		$37K Buy
4,143
+522
+14% +$5K ﹤0.01% 8821
2019
Q1 		$35K Buy
+3,621
New +$39.9K ﹤0.01% 8955
2017
Q2 		– Sell
-1,193
Closed -$27K – 8352
2017
Q1 		$27K Sell
1,193
-682
-36% -$10.7K ﹤0.01% 7192
2016
Q4 		$15K Buy
1,875
+730
+64% +$10.2K ﹤0.01% 7130
2016
Q3 		$24K Buy
1,145
+339
+42% +$8.18K ﹤0.01% 7005
2016
Q2 		$21K Buy
+806
New +$22.1K ﹤0.01% 6593

Other funds holding BLPH

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citadel Advisors's BLPH Position: Q4 2023 in Review

Citadel Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 42,717 shares — an estimated $17.1K sold.

Citadel Advisors first reported a position in BLPH in Q2 2016 and held it in 9 quarters. The position peaked at $104K in Q1 2021. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.

  • Citadel Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 42,717 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $17.1K.
  • Citadel Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q2 2016 and held it in 9 quarters.
  • Citadel Advisors's Bellerophon Therapeutics, Inc. position peaked at $104K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.